Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar-Apr;10(2):105-8.
doi: 10.1016/j.reuma.2013.07.007. Epub 2013 Sep 10.

Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis

[Article in English, Spanish]
Francisca Llinares-Tello  1 , José Rosas  2 , Inmaculada de la Torre  3 , Lara Valor  3 , Xavier Barber  4 , José Miguel Senabre  5 ; el Grupo AIRE-MB, HUGM
Collaborators, Affiliations
Free article
Comparative Study

Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis

[Article in English, Spanish]
Francisca Llinares-Tello et al. Reumatol Clin. 2014 Mar-Apr.
Free article

Abstract

Objective: To describe the results of the comparative study between both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab (ADA) in rheumatoid arthritis (AR).

Material and methods: 140 samples of patients with RA treated with ADA 40mg every 14 days were analyzed by both versions of the test (V1 or previous and V2 or updated).

Results: A good correlation was obtained by both versions. In general V2 provides higher results of ADA's concentration than V1 and presents greater precision in the range of concentrations for clinical decisions, adjusting for the real concentration of the drug in blood. In addition, V2 allows for complete automation, which simplifies the analysis and reduces significantly the variability.

Conclusion: ADA's monitoring with the updated version demonstrated to have technical significant advantages, constituting a more practical tool for therapeutic decisions in patients with RA.

Keywords: Adalimumab; Anti-adalimumab antibodies; Anticuerpos antiadalimumab; Enzime linked immunosorbent assay; Enzimoinmunoanálisis; Monitorización terapéutica de fármacos; Therapeutic drug monitoring.

PubMed Disclaimer

Publication types

MeSH terms